---
title: "DRS combination of scaffold and antirestenotic drug will “really advance” treatment options and improve patency in CLTI patients"
date: "2024-01-05T10:37:23.000Z"
publishedDate: "5 janvier 2024"
summary: "Principal investigators of the LIFE-BTK randomised controlled trial delve into the technological improvements underpinning the Esprit drug-eluting resorbable scaffold (DRS; Abbott) from its previous iteration used in the coronaries, while discussing how this trial places this device at the heart of infrapopliteal disease treatment for critical limb-threatening ischaemia (CLTI) patients. Sahil A Parikh (Columbia [&#8230;] The post DRS combination of scaffold and antirestenotic drug will “really advance” treatment options and improve patency in CLTI patients appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/drs-combination-of-scaffold-and-antirestenotic-drug-will-really-advance-treatment-options-and-improve-patency-in-clti-patients/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2024-01-05-drs-combination-of-scaffold-and-antirestenotic-drug-will-really-advance-treatment-options-and-improve-patency-in-clti-patients"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2024/01/Varcoe-Parikh-DeRubertis-VIVA-web.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/drs-combination-of-scaffold-and-antirestenotic-drug-will-really-advance-treatment-options-and-improve-patency-in-clti-patients/"
---

![DRS combination of scaffold and antirestenotic drug will “really advance” treatment options and improve patency in CLTI patients](https://vascularnews.com/wp-content/uploads/sites/7/2024/01/Varcoe-Parikh-DeRubertis-VIVA-web.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/drs-combination-of-scaffold-and-antirestenotic-drug-will-really-advance-treatment-options-and-improve-patency-in-clti-patients/*

## L’essentiel

Principal investigators of the LIFE-BTK randomised controlled trial delve into the technological improvements underpinning the Esprit drug-eluting resorbable scaffold (DRS; Abbott) from its previous iteration used in the coronaries, while discussing how this trial places this device at the heart of infrapopliteal disease treatment for critical limb-threatening ischaemia (CLTI) patients. Sahil A Parikh (Columbia [&#8230;] The post DRS combination of scaffold and antirestenotic drug will “really advance” treatment options and improve patency in CLTI patients appeared first on Vascular News .

## Lien source

https://vascularnews.com/drs-combination-of-scaffold-and-antirestenotic-drug-will-really-advance-treatment-options-and-improve-patency-in-clti-patients/
